Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ixmyelocel-T
- Development stage
- Phase 3
- Lead developer
- Vericel
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial, Transendocardial
01
Overview
Ixmyelocel-T is an autologous, expanded multicellular therapy derived from a patient's own bone marrow. It is produced using the proprietary Aastrom Replicell System, which selectively expands specific cell populations—primarily CD90+ mesenchymal stem cells and CD14+ monocytes/macrophages (polarized toward an M2 anti-inflammatory phenotype)—while significantly reducing the number of granulocytes. The therapy was developed by Vericel Corporation (formerly Aastrom Biosciences) and was primarily investigated for the treatment of ischemic cardiovascular conditions, including critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). Despite reaching Phase 2b clinical trials (the RESTORE-CLI and ix-CELL-DCM studies), Vericel announced in 2016 that it would discontinue the development of ixmyelocel-T to focus resources on its commercial cartilage and skin repair products.
- Other names
- ixmyelocel-Tautologous expanded multicellular therapy
Beyond the preview
Go deeper on ixmyelocel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ixmyelocel-T.